Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

First-Line Nivolumab In Stage IV Or Recurrent Non-Small Cell Lung Cancer

D. Carbone
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share



This paper is referenced by
10.21873/invivo.11503
Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases
Y. Akano (2019)
Anti-PDL 1 effect in squamous non-small cell lung cancer
M. Rahouma (2020)
10.2147/CMAR.S179680
Predictive biomarkers for tumor immune checkpoint blockade
Mengting Tong (2018)
10.1371/journal.pone.0202725
Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan
J. C. Hsu (2018)
10.1080/17476348.2020.1681977
Nivolumab for the treatment of small cell lung cancer
E. Simeone (2019)
10.2147/CMAR.S218635
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer
M. Schabath (2019)
10.13023/ETD.2018.045
EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER
Sherif M. El-Refai (2018)
10.21037/20960
Atezolizumab: state of art and future perspective in non-small cell lung cancer treatment
S. Vecchiarelli (2018)
10.1371/journal.pone.0215292
Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations
M. Sato (2019)
10.1101/745265
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
R. Barroso-Sousa (2019)
10.1101/mcs.a003251
A case study of a long-term glioblastoma survivor with unmethylated MGMT and hypermutated genotype
T. R. Jue (2019)
10.1038/s41392-020-00324-2
Overview of current targeted therapy in gallbladder cancer
Xiao-ling Song (2020)
10.1001/jamanetworkopen.2020.17675
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
David Bomze (2020)
10.3390/cancers12061685
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
S. Schatz (2020)
10.1136/jitc-2020-000552
LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
Niklas Klümper (2020)
10.3390/cancers12123729
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
L. Boyero (2020)
10.1186/s40425-018-0421-z
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
B. Zhao (2018)
10.1101/419424
Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancer
D. Wang (2018)
10.3389/fonc.2020.01300
A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients With Lung Adenocarcinoma
Cong-kuan Song (2020)
10.3779/j.issn.1009-3419.2019.06.07
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Di Zhang (2019)
10.18632/aging.102556
Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma
Run-Cong Nie (2019)
10.1038/s41598-020-70207-7
Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
P. Cui (2020)
10.3390/cancers12102983
The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
Ravindra Pramod Deshpande (2020)
10.3779/j.issn.1009-3419.2020.101.35
[Progress in Treatment of Advanced Squamous Cell Lung Cancer].
M. Gao (2020)
10.35841/CANCER-IMMUNOLOGY.1.1.1-2
Current state of immunotherapy: chipping away at the tip of the iceberg.
N. Mohindra (2018)
10.15406/bbij.2018.07.00260
A review of statistical methods on testing time-to-event data
T. Xu (2018)
10.21037/jtd.2018.12.103
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
S. Lantuéjoul (2019)
10.1186/s40425-018-0442-7
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
V. Verma (2018)
10.21427/JKNP-X470
Raman Microspectroscopy for the Discrimination of Thyroid and Lung Cancer Subtypes for Application in Clinical Cytopathology
Declan O'Dea (2020)
10.1038/s41597-019-0332-y
Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer
Rumana Rashid (2019)
10.3389/fonc.2019.01394
Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study
Valentina Masciale (2019)
10.1080/14712598.2019.1606209
Immune checkpoint inhibition for the treatment of mesothelioma
A. Nowak (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar